The Ninth pan-European Conference on PAT and QbD Sciences
EuPAT brings together pharmaceutical scientists and engineers from industry, academia and regulatory agencies to discuss recent developments and future trends in the field of pharmaceutical product and process development. The 9th EuPAT conference will focus on the status of QbD in pharmaceutical development, the latest advances in continuous manufacture and emerging developments in the manufacture and analysis of nanomedicines. Session content will describe technological developments, regulatory issues and recent experiences in drug development projects.
The conference builds on the success of the EuPAT series established in 2006 and will be organised by EUFEPS and its QbD and PAT Sciences Network in partnership with colleagues from The University of Manchester, North West Centre for Advanced Drug Delivery (NoWCADD) and Manchester Institute of Biotechnology (MIB), AstraZeneca, Croda Europe and Malvern Instruments. The main meeting will be held on May 15th and 16th, 2018, at The Museum of Science and Industry (MOSI), Manchester, UK and will be preceded by a pre-conference workshop focussed on “Innovations in the design, manufacture and analysis of nanomedicines”, which is scheduled to take place on May 14th, 2018. This meeting will comprise talks from high profile industrial and academic speakers and will be held at The University of Manchester. Plans are also being established for a site visit to AstraZeneca’s Macclesfield Campus in nearby Cheshire where delegates will get the chance to tour the product development facility whilst listening to the experiences of AstraZeneca staff involved in recent innovation projects. The attendees of EuPAT9 are welcome to register for the pre-conference day.
See website for preliminary programme, abstract submission, pre-conference workshop, exhibition and sponsorship options, early-bird and later fees, registration
and accommodation information.
Session Topics and invited speakers at EuPAT 9
• Current industrial and regulatory perspectives on QbD in (bio)pharmaceutical development
Dr David Holt (AstraZeneca, UK)
Greg Troiano (Pfizer, USA)
• Emerging developments in the manufacture and analysis of nanomedicines
Neill Liptrott (European Nanomedicines Laboratory, UK)
Alon Vaisman (Malvern Instruments, USA)
• The emerging digital revolution in (bio)pharmaceutical product design and manufacture
Dr Sean Bermingham (PSE Ltd, UK)
Dr Blair Johnston (CMAC, University of Strathclyde, UK)
• Innovations in continuous manufacturing science and technology for biologicals and pharmaceuticals
Prof Agba Salman (University of Sheffield, UK)
Martin Warman (Martin Warman Consultancy Ltd, UK)